Perioperative Pregabalin and Lidocaine to Reduce Chronic Breast Cancer Pain

McMaster University100 enrolled

Overview

Breast tissue and the areas surrounding the breast contain many small to medium-sized nerves. During surgery on the breast, these nerves can be inadvertently cut or damaged. Chemotherapy and radiotherapy after surgery worsen the injury experienced by these nerves. These nerves eventually become abnormal and provide pain signals to the brain well beyond the healing period after surgery. Patients with these abnormal nerves suffer from chronic pain in the breast area that persists for several years after surgery. Chronic pain is associated with a reduced quality of life, daily functioning, psychological distress, and contributes to excessive health care expenditures. There is encouraging data suggesting that an infusion of Lidocaine during surgery and Pregabalin given around the time of surgery can prevent the development of chronic pain after breast cancer surgery. A large randomized controlled trial is needed to determine the efficacy of these two interventions on reducing chronic pain after breast cancer surgery (e.g. within 3 months of surgery). A pilot trial is first needed to determine the feasibility of undertaking such a trial.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

100

Conditions

Post-mastectomy Pain Syndrome Chronic Post-surgical Pain

Interventions

Intraoperative Intravenous Lidocaine InfusionDRUG

Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.

Perioperative PregabalinDRUG

Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.

Perioperative Pregabalin PlaceboDRUG

Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.

Intraoperative Intravenous Lidocaine Placebo InfusionDRUG

Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * female patients 18-75 years of age * undergoing a unilateral or bilateral mastectomy or partial-mastectomy (breast conserving surgery), for prophylactic (e.g. family history or BRCA gene mutation) or belief of isolated (non-metastatic) cancerous lesions * receiving a general anesthetic Exclusion Criteria: * previous breast surgery within six months of index surgery * undergoing a DIEP (Deep Inferior Epigastric Perforator) flap procedure * patient has chronic pain or a chronic pain syndrome for which they have taken 4 or more daily medications (i.e. opioids, anti-convulsants, anti-spasmodic, anti-depressants, anti-inflammatories) or routine pain intervention (i.e. nerve blocks) during the past 3 months * documented hypersensitivity or allergy to pregabalin, gabapentin, or lidocaine * history of ventricular tachycardia, ventricular fibrillation, or atrioventricular block ≥ type II * history of congestive heart failure * renal insufficiency with creatinine \> 120 µmol/L * known or previously documented cirrhosis * pregnant * unable to swallow study medications * patient's surgeon believes patient is inappropriate for inclusion in trial * unlikely to comply with follow-up (e.g. no fixed address, plans to move out of town) * language difficulties that would impede valid completion of questionnaires * patient requires gabapentin or pregabalin for a medical condition or has been taking gabapentin or pregabalin daily during the past 1 week

Outcomes

Primary Outcomes

Feasibility

The feasibility outcome will be measured by the rate of recruitment, compliance, percentage of patient's with complete follow-up and site resource requirements.

Time frame: 6 months

Secondary Outcomes

Post-mastectomy pain syndrome

Time frame: 6 months

Length of hospital stay

Most breast cancer surgeries are day procedures, therefore length of hospital stay will be measured based on whether or not the patient was discharged from the hospital on the same day as surgery or if they were admitted and remained in hospital overnight.

Time frame: Total number of overnight stays spent in hospital continuously from the day of surgery until a maximum of 3 months post-operatively.

Quality of Life

Time frame: 3 months

Somatic Pre-occupation and Coping Scale